492 related articles for article (PubMed ID: 28814763)
21. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
Brown RD; Pope B; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
[TBL] [Abstract][Full Text] [Related]
22. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.
Lohr JG; Kim S; Gould J; Knoechel B; Drier Y; Cotton MJ; Gray D; Birrer N; Wong B; Ha G; Zhang CZ; Guo G; Meyerson M; Yee AJ; Boehm JS; Raje N; Golub TR
Sci Transl Med; 2016 Nov; 8(363):363ra147. PubMed ID: 27807282
[TBL] [Abstract][Full Text] [Related]
23. Oncogenes in multiple myeloma: point mutation of N-ras.
Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
Abdalla S; May PC; Garimberti E; Naresh KN
Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
[No Abstract] [Full Text] [Related]
25. Multiple myeloma clonal evolution in homogeneously treated patients.
Corre J; Cleynen A; Robiou du Pont S; Buisson L; Bolli N; Attal M; Munshi N; Avet-Loiseau H
Leukemia; 2018 Dec; 32(12):2636-2647. PubMed ID: 29895955
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.
Mithraprabhu S; Khong T; Ramachandran M; Chow A; Klarica D; Mai L; Walsh S; Broemeling D; Marziali A; Wiggin M; Hocking J; Kalff A; Durie B; Spencer A
Leukemia; 2017 Aug; 31(8):1695-1705. PubMed ID: 27899805
[TBL] [Abstract][Full Text] [Related]
27. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
28. Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
Leone PE; Walker BA; Jenner MW; Chiecchio L; Dagrada G; Protheroe RK; Johnson DC; Dickens NJ; Brito JL; Else M; Gonzalez D; Ross FM; Chen-Kiang S; Davies FE; Morgan GJ
Clin Cancer Res; 2008 Oct; 14(19):6033-41. PubMed ID: 18829482
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma.
Hao Y; Khaykin D; Machado L; van den Akker T; Houldsworth J; Barlogie B; Hussein S; El Jamal SM; Petersen B; Teruya-Feldstein J
Mod Pathol; 2020 Feb; 33(2):188-195. PubMed ID: 31375765
[TBL] [Abstract][Full Text] [Related]
30. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
[TBL] [Abstract][Full Text] [Related]
31. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.
Merz M; Merz AMA; Wang J; Wei L; Hu Q; Hutson N; Rondeau C; Celotto K; Belal A; Alberico R; Block AW; Mohammadpour H; Wallace PK; Tario J; Luce J; Glenn ST; Singh P; Herr MM; Hahn T; Samur M; Munshi N; Liu S; McCarthy PL; Hillengass J
Nat Commun; 2022 Feb; 13(1):807. PubMed ID: 35145077
[TBL] [Abstract][Full Text] [Related]
32. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
Klein B; Seckinger A; Moehler T; Hose D
Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
[TBL] [Abstract][Full Text] [Related]
33. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
34. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
35. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
36. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
[TBL] [Abstract][Full Text] [Related]
37. FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma.
Zhang W; Wu C; Geng S; Wang J; Yan C; Zhang X; Zhang JJ; Wu F; Pang Y; Zhong Y; Wang J; Fu W; Huang X; Wang W; Lyu X; Huang Y; Jing H
Aging (Albany NY); 2023 May; 15(9):3644-3677. PubMed ID: 37155154
[TBL] [Abstract][Full Text] [Related]
38. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
39. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Weinhold N; Ashby C; Rasche L; Chavan SS; Stein C; Stephens OW; Tytarenko R; Bauer MA; Meissner T; Deshpande S; Patel PH; Buzder T; Molnar G; Peterson EA; van Rhee F; Zangari M; Thanendrarajan S; Schinke C; Tian E; Epstein J; Barlogie B; Davies FE; Heuck CJ; Walker BA; Morgan GJ
Blood; 2016 Sep; 128(13):1735-44. PubMed ID: 27516441
[TBL] [Abstract][Full Text] [Related]
40. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Brioli A; Melchor L; Cavo M; Morgan GJ
Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
